Our work in drug-resistant TB
The Union advocates for increased research and development, and conducts clinical trials to reduce treatment time and improve outcomes for patients in countries with the highest burdens of disease.
The Union also provides practical and experience-based support to countries implementing care for people with DR-TB. Our expertise is based on our extensive research with partners supporting the nine-month regimen, including partnering on the first randomised control trial into a new regimen for multidrug-resistant TB (TREAT TB).
With the new World Health Organization guidelines focusing on shorter, all oral, regimens for MDR-TB, The Union continues to support countries to implement the latest evidence-based treatments.
TREAT TB
Read more about TREAT TB (Technology, Research, Education and Technical Assistance for Tuberculosis), an ambitious initiative that was launched by The Union, seeking to contribute new knowledge regarding shorter, more tolerable treatment regimens for MDR-TB.
OTHER AREAS OF OUR WORK IN TUBERCULOSIS
You might also be interested in our work on child and adolescent TB and TB-HIV, TB-diabetes and co-morbidities.
The Union used an operational research approach to test a shortened treatment regimen for multidrug-resistant TB. The study first demonstrated a greater than 80% success rate in Bangladesh, Cameroon and Niger and The Union continued to work to develop and implement shorter more effective regimens for the treatment of MDR-TB.
Learn more
Understand the issues with our fact sheets
DR-TB Union news
Managing household contacts of individuals with rifampicin-resistant tuberculosis
In the last ten years, the epidemiology, diagnosis and treatment of multidrug-resistant (MDR) or rifampicin-resistant tuberculosis (RR-…
Celebrating a year of learning: thank you to our course participants!
Reflecting on the past year, we extend our sincere thanks to the dedicated learners who joined us in our mission to combat…
Scholarship for drug-resistant TB course announced in memory of leading public health physician
A key group within the International Union Against Tuberculosis and Lung Disease (The Union) announced the establishment of a…
A year in review – evaluating the launch of IJTLD OPEN
An Editorial in a forthcoming issue of IJTLD OPEN describes how open access has driven a dramatic increase in visibility.
Loss to follow-up among adults with drug-resistant TB in Papua New Guinea
An article in a forthcoming issue of PHA assesses the reasons for loss-to-follow-up in patients being treated for disease resistant TB.